SCHEMBL29622932

SCHEMBL29622932

CCOC(=O)C(F)(F)C(O)c1ccc(F)cc1Br

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FBP1 P09467 1/20 0.39
MAPT P10636 5/20 0.38
POLB P06746 2/20 0.38
APLNR P35414 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
PKM P14618 1/20 0.37
HTT P42858 1/20 0.36
TSHR P16473 2/20 0.35
MEN1 O00255 1/20 0.34
LMNA P02545 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
KMT2A Q03164 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
MMP8 P22894 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21857875 1.00 FBP1 (0.39) FBP1MAPTPOLBAPLNRSMN1; SMN2
SCHEMBL15093901 0.90 FBP1 (0.39) FBP1MAPTPOLBSMN1; SMN2PKM
SCHEMBL12253316 0.82 PIN1 (0.43) MAPTPOLBHTTTSHRLMNA
SCHEMBL25757431 0.80 APLNR (0.37) MAPTAPLNRSMN1; SMN2PKMRAB9A
SCHEMBL362742 0.79 ALOX5 (0.38) FBP1MAPTSMN1; SMN2MEN1LMNA
SCHEMBL15094412 0.79 FBP1 (0.39) FBP1MAPTPOLBSMN1; SMN2PKM
SCHEMBL29570205 0.77 MAPT (0.46) FBP1MAPTSMN1; SMN2TSHRMEN1
SCHEMBL29571136 0.76 PPARA (0.42) FBP1MAPTSMN1; SMN2TSHRMEN1
SCHEMBL21857987 0.76 SMN1; SMN2 (0.33) FBP1MAPTPOLBSMN1; SMN2TSHR
SCHEMBL21858005 0.76 F2R (0.40) FBP1MAPTPOLBSMN1; SMN2PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115485262-B Hypoxia inducible factor-2 (alpha) inhibitors and their use in the treatment of disease 霖康疗法公司 2025-04-04 CN disclosed
CN-118993938-A Tetrahydro-1H-cyclopenta [ CD ] indene derivatives as hypoxia inducible factor-2 (alpha) inhibitors 尼坎治疗公司 2024-11-22 CN disclosed
CN-118993939-A Tetrahydro-1H-cyclopenta [ CD ] indene derivatives as hypoxia inducible factor-2 (alpha) inhibitors 尼坎治疗公司 2024-11-22 CN disclosed
CN-113874350-B Tetrahydro-1H-cyclopenta [ CD ] indene derivatives as hypoxia inducible factor-2 (alpha) inhibitors 尼坎治疗公司 2024-08-06 CN disclosed
CN-116507601-A Process for preparing 3-fluoro-5- (((1S, 2 aR) -1,3, 4-pentafluoro-2 a-hydroxy-2, 2a,3, 4-tetrahydro-1H-cyclopenta [ cd ] inden-7-yl) oxy) benzonitrile 尼坎治疗公司 2023-07-28 CN disclosed
WO-2023070483-A1 PROCESSES OF MAKING 3-FLUORO-5- ( ( (1R, 2S, 2aS) -1, 2, 3, 3, 4, 4-HEXAFLUORO-2A-HYDROXY-2, 2A, 3, 4-TETRAHYDRO-1H-CYCLOPENTA [CD] INDEN-7-YL) -OXY) -BENZONITRILE AND POLYMORPHS THEREOF NIKANG THERAPEUTICS, INC. (US) 2023-05-04 WO disclosed
EP-4136069-A1 HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASES Nikang Therapeutics, Inc. (US) 2023-02-22 EP disclosed
CN-115485262-A Hypoxia inducible factor-2 (alpha) inhibitors and their use in the treatment of disease 尼坎治疗公司 2022-12-16 CN disclosed
WO-2022082337-A1 PROCESS OF PREPARING 3-FLUORO-5 ( ( (1R, 2AR) -3, 3, 4, 4-TETRAFLUORO-1, 2A-DIHYDROXY-2, 2A, 3, 4-TETRAHYDRO-1H-CYCLOPENTA [CD] INDEN-7-YL) OXY) BENZONITRILE NIKANG THERAPEUTICS, INC. (US) 2022-04-28 WO disclosed